Cheyne Capital Management (Uk) LLP Travere Therapeutics, Inc. Transaction History
Cheyne Capital Management (Uk) LLP
- $26.1 Million
- Q4 2023
Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
214Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$157 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$151 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$138 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$102 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$87.4 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.32B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...